Trials / Completed
CompletedNCT02487225
Pentoxifylline Treatment in Acute Pancreatitis (AP)
Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.
Detailed description
Participants were randomized to either the treatment group (Pentoxifylline medication) or the control group (Placebo). Participant took a pill orally, starting from the time of admission. Participants received a total of 9 doses over the three days of hospitalization (72 hours). Research blood draws were done at baseline and on 5 successive days or until the time of discharge, whichever occured earlier. The study gathered clinical follow up information up to 4 months following hospitalization regarding the diagnosis of acute pancreatitis.
Conditions
- Acute Pancreatitis (AP)
- Gallstone Pancreatitis
- Alcoholic Pancreatitis
- Trauma Acute Pancreatitis
- Hypertriglyceridemia Acute Pancreatitis
- Idiopathic (Unknown) Acute Pancreatitis
- Medication Induced Acute Pancreatitis
- Cancer Acute Pancreatitis
- Miscellaneous (i.e. Acute on Chronic Pancreatitis)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentoxifylline | Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors |
| DRUG | Placebo | A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-04-30
- Completion
- 2017-10-31
- First posted
- 2015-07-01
- Last updated
- 2019-01-23
- Results posted
- 2019-01-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02487225. Inclusion in this directory is not an endorsement.